Interplay of miRNA-146a and miRNA-126 in Chronic Periodontitis Patients With Coronary Artery Disease

Study Overview
=================
Brief Summary
-----------------
The role of micro-RNAs in chronic periodontitis associated with CAD is still in an incipient stage needs to be explored further. The investigators attempt to quantify and compare the levels of micro-RNA 146a and micro-RNA 126 in subgingival as well as coronary plaque samples obtained from patients diagnosed with chronic periodontitis with and without coronary artery disease.

Detailed Description
-----------------
The role of micro-RNAs in chronic periodontitis associated with CAD is still in an incipient stage needs to be explored further. The investigators attempt to quantify and compare the levels of micro-RNA 146a and micro-RNA 126 in subgingival as well as coronary plaque samples obtained from patients diagnosed with chronic periodontitis with and without coronary artery disease. Seventy-five participants were selected and grouped into 3 categories; 25 patients diagnosed with chronic periodontitis and coronary artery disease: CP + CAD group; 25 patients diagnosed with chronic periodontitis alone: CP group; and 25 systemically and periodontally healthy controls (HP). Demographic variables, periodontal parameters, cardiac parameters, blood pressure were obtained. miRNA-146a and miRNA126 levels were assessed in subgingival plaque (SP) samples from all the three groups. Within CP+CAD group, SP samples of CP+CADa were compared with coronary plaques samples (CP) of CP+CADb while the patient underwent CABG.

Official Title
-----------------
Interplay of miRNA-146a and miRNA-126 in Chronic Periodontitis Patients With Coronary Artery Disease

Conditions
-----------------
Chronic Periodontitis, Coronary Artery Disease, miRNA

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients volunteering for the investigation. Patients between the age group of 30-70 years Presence of ≥ 15 natural teeth. Exclusion criteria: Patients associated with systemic diseases such as lung disorders, renal disease, liver disease, type I, type II-diabetes mellitus, HIV infection, rheumatoid arthritis, allergy or any malignancy. Under treatment with antibiotics, immunosuppressive drugs such as corticosteroids, within 6 months. Pregnant women and female patients were excluded because of the altered oral flora due to hormonal changes Smoking and other tobacco usage habits Patients who underwent periodontal treatment within 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CP + CHD group<br>This was further divided into CP + CHDa (Subgingival plaque) and CP + CHDb (Coronary plaque) based on the nature of plaque collected. | |
| CP group<br>25 patients with chronic periodontitis who were systemically healthy were selected | |
| HP group<br>25 patients who were systemically and periodontally healthy, were considered as HP group. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| micro-RNA 146-a expression in Chronic periodontitis patients with and without coronary heart disease. | microRNA 146-a expression was present in the chronic periodontitis subjects with coronary heart disease | 10 months | 
| Levels of micro-RNA 126 in chronic periodontitis patients with and without coronary heart disease | microRNA 126 expression was present in chronic periodontitis subjects with coronary heart disease | 10 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Periodontitis, coronary artery disease, microRNA 146a, microRNA 126, plaque samples, biomarkers